58040IGNITE Data – mitigating disruption to clinical trial managementClosedFeasibility StudiesInnovate UKClinical research has been severely impacted by the Covid-19 pandemic. One of the key factors affecting doctors and researchers' ability to conduct clinical studies under Covid-19 conditions is the current need to manually review and transfer data between databases held by different providers. This situation has been worsened by the need to redeploy or isolate staff who'd normally perform this data transcription. This has inhibited clinicians/researchers' ability to initiate and manage clinical studies effectively, including those seeking therapeutic or diagnostic approaches that could directly benefit Covid-19 patients. IGNITE Data is a leading British business that specialises in helping organisations set-up and manage clinical trials effectively. Its Archer platform is an innovative digital-health tool that uses advanced software to enable data to be transferred more easily between critical healthcare systems. The proposed project will help it to fulfil its potential to reduce the disruption currently affecting clinical research, helping new medicines and diagnostic tests to be developed more quickly for a variety of diseases and applications, including for Covid-19 itself. The extension for impact funding will help catalyse the commercialisation of the Archer platform by enabling IGNITE Data to connect to a critical healthcare system that underpins many UK clinical trials.